Purple Biotech Ltd. [NASDAQ: PPBT] traded at a low on 06/04/21, posting a -11.76 loss after which it closed the day’ session at $5.93. The company report on June 4, 2021 that Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting.
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors.
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer.
The results of the trading session contributed to over 4981167 shares changing hands. Over the past one week, the price volatility of Purple Biotech Ltd. stands at 18.08% while the volatility over the past one month is 8.51%.
The market cap for PPBT stock reached $103.84 million, with 17.51 million shares outstanding and 16.24 million shares in the current float. Compared to the average trading volume of 393.75K shares, PPBT reached a trading volume of 4981167 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Purple Biotech Ltd. [PPBT]?
The Average True Range (ATR) for Purple Biotech Ltd. is set at 0.49, with the Price to Sales ratio for PPBT stock in the period of the last 12 months amounting to 103.84.
How has PPBT stock performed recently?
Purple Biotech Ltd. [PPBT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.13. With this latest performance, PPBT shares gained by 46.78% in over the last four-week period, additionally plugging by 39.53% over the last 6 months – not to mention a rise of 25.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PPBT stock in for the last two-week period is set at 66.23, with the RSI for the last a single of trading hit 65.79, and the three-weeks RSI is set at 64.49 for Purple Biotech Ltd. [PPBT]. The present Moving Average for the last 50 days of trading for this stock 4.41, while it was recorded at 6.10 for the last single week of trading, and 4.42 for the last 200 days.
Purple Biotech Ltd. [PPBT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Purple Biotech Ltd. [PPBT] shares currently have an operating margin of -1275.10. Purple Biotech Ltd.’s Net Margin is presently recorded at -2799.90.
Return on Total Capital for PPBT is now -29.51, given the latest momentum, and Return on Invested Capital for the company is -65.68. Return on Equity for this stock declined to -66.20, with Return on Assets sitting at -60.20. When it comes to the capital structure of this company, Purple Biotech Ltd. [PPBT] has a Total Debt to Total Equity ratio set at 1.13. Additionally, PPBT Total Debt to Total Capital is recorded at 1.11, with Total Debt to Total Assets ending up at 1.07. Long-Term Debt to Equity for the company is recorded at 0.87, with the Long-Term Debt to Total Capital now at 0.86.
Reflecting on the efficiency of the workforce at the company, Purple Biotech Ltd. [PPBT] managed to generate an average of -$7,406,876 per employee. Receivables Turnover for the company is 1.02 with a Total Asset Turnover recorded at a value of 0.02.
Insider trade positions for Purple Biotech Ltd. [PPBT]
There are presently around $4 million, or 24.90% of PPBT stock, in the hands of institutional investors. The top three institutional holders of PPBT stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 219,035, which is approximately 69.926% of the company’s market cap and around 1.88% of the total institutional ownership; MORGAN STANLEY, holding 167,804 shares of the stock with an approximate value of $0.99 million in PPBT stocks shares; and CITADEL ADVISORS LLC, currently with $0.38 million in PPBT stock with ownership of nearly New of the company’s market capitalization.
Positions in Purple Biotech Ltd. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 9 institutional holders increased their position in Purple Biotech Ltd. [NASDAQ:PPBT] by around 200,523 shares. Additionally, 12 investors decreased positions by around 731,048 shares, while 3 investors held positions by with 333,868 shares. The mentioned changes placed institutional holdings at 597,703 shares, according to the latest SEC report filing. PPBT stock had 6 new institutional investments in for a total of 99,717 shares, while 8 institutional investors sold positions of 85,516 shares during the same period.